# AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

> **NCT06137118** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 163 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia (B-ALL)

## Interventions

- **DRUG:** AZD0486

## Key facts

- **NCT ID:** NCT06137118
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-29
- **Primary completion:** 2026-11-13
- **Final completion:** 2027-06-29
- **Target enrollment:** 163 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137118, "AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06137118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*